Active substance
Streptokinase
- SFDA 4
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| KABIKINASE 600000 IU VIAL | 600000 IU | Injection · Intravenous use | 1 Vial | SAR 95.90 | Biological · Prescription | OCTAPHARMA | Withdrawn by MAH · Not Marketed |
| KABIKINASE VIAL 100000 IU | 100000 IU | Injection · Intravenous use | 1 Vial | SAR 59.35 | Biological · Prescription | OCTAPHARMA | Withdrawn by MAH · Not Marketed |
| STREPTAS 250000I.U VIAL | 250000 IU | Injection · Intravenous use | 1 Vial | SAR 163.40 | Biological · Prescription | CSL | Withdrawn by MAH · Not Marketed |
| STREPTAS 750000I.U VIAL | 750000 IU | Injection · Intravenous use | 1 Vial | SAR 249.45 | Biological · Prescription | CSL | Withdrawn by MAH · Not Marketed |
WHO WHO Model List of Essential Medicines (2025)
- 12.5.2. Thrombolytic medicines · complementary
Acute myocardial infarction
Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.